<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30376097</PMID><DateCompleted><Year>2019</Year><Month>11</Month><Day>18</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-6591</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>suppl_1</Issue><PubDate><Year>2018</Year><Month>Oct</Month><Day>30</Day></PubDate></JournalIssue><Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title><ISOAbbreviation>Clin Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Characterization of Household and Community Shedding and Transmission of Oral Polio Vaccine in Mexican Communities With Varying Vaccination Coverage.</ArticleTitle><Pagination><StartPage>S4</StartPage><EndPage>S17</EndPage><MedlinePgn>S4-S17</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/ciy650</ELocationID><Abstract><AbstractText Label="BACKGROUND">The World Health Assembly 2012 Polio Eradication and Endgame Strategic Plan calls for the eventual cessation of all oral polio vaccines (OPVs), to be replaced with inactivated polio vaccine (IPV); however, IPV induces less robust mucosal immunity than OPV. This study characterized household and community OPV shedding and transmission after OPV vaccination within primarily IPV-vaccinated communities.</AbstractText><AbstractText Label="METHODS">Households in 3 IPV-vaccinated Mexican communities were randomized to receive 3 levels of OPV vaccination coverage (70%, 30%, or 10%). Ten stool samples were collected from all household members over 71 days. Analysis compared vaccinated subjects, household contacts of vaccinated subjects, and subjects in unvaccinated households. Logistic and Cox regression models were fitted to characterize transmission of OPV by coverage and household vaccination status.</AbstractText><AbstractText Label="RESULTS">Among 148 vaccinated children, 380 household contacts, and 1124 unvaccinated community contacts, 78%, 18%, and 7%, respectively, shed OPV. Community and household contacts showed no differences in transmission (odds ratio [OR], 0.67; 95% confidence interval [CI], .37-1.20), in shedding trajectory (OR, 0.61; 95% CI, .35-1.07), or in time to shedding (hazard ratio, 0.68; 95% CI, .39-1.19). Transmission began as quickly as 1 day after vaccination and persisted as long as 71 days after vaccination. Transmission within unvaccinated households differed significantly across vaccination coverage communities, with the 70% community experiencing the most transmissions (15%), and the 10% community experiencing the least (4%). These trends persisted over time and in the time to first shedding analyses.</AbstractText><AbstractText Label="CONCLUSIONS">Transmission did not differ between household contacts of vaccinees and unvaccinated households. Understanding poliovirus transmission dynamics is important for postcertification control.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Altamirano</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Stanford University School of Medicine, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Purington</LastName><ForeName>Natasha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Stanford University School of Medicine, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Behl</LastName><ForeName>Rasika</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Stanford University School of Medicine, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarnquist</LastName><ForeName>Clea</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Stanford University School of Medicine, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holubar</LastName><ForeName>Marisa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Stanford University School of Medicine, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Garc&#xed;a</LastName><ForeName>Lourdes</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Salud P&#xf9;blica, Cuernavaca, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferreyra-Reyes</LastName><ForeName>Leticia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Salud P&#xf9;blica, Cuernavaca, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montero-Campos</LastName><ForeName>Rogelio</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Salud P&#xf9;blica, Cuernavaca, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruz-Hervert</LastName><ForeName>Luis Pablo</ForeName><Initials>LP</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Salud P&#xf9;blica, Cuernavaca, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universidad Nacional Aut&#xf3;noma de M&#xe9;xico (UNAM), Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyle</LastName><ForeName>Shanda</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Bill &amp; Melinda Gates Foundation, Seattle, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Modlin</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Bill &amp; Melinda Gates Foundation, Seattle, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Hoorebeke</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Stanford University School of Medicine, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leary</LastName><ForeName>Sean</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Stanford University School of Medicine, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>ChunHong</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Stanford University School of Medicine, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sommer</LastName><ForeName>Marvin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Stanford University School of Medicine, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferreira-Guerrero</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Salud P&#xf9;blica, Cuernavaca, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delgado-Sanchez</LastName><ForeName>Guadalupe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Salud P&#xf9;blica, Cuernavaca, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Canizales-Quintero</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Salud P&#xf9;blica, Cuernavaca, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xed;az Ortega</LastName><ForeName>Jos&#xe9; Luis</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Salud P&#xf9;blica, Cuernavaca, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desai</LastName><ForeName>Manisha</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Stanford University School of Medicine, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maldonado</LastName><ForeName>Yvonne A</ForeName><Initials>YA</Initials><AffiliationInfo><Affiliation>Stanford University School of Medicine, California.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 AI052073</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Infect Dis</MedlineTA><NlmUniqueID>9203213</NlmUniqueID><ISSNLinking>1058-4838</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062665" MajorTopicYN="N">Epidemiological Monitoring</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005191" MajorTopicYN="N">Family Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008800" MajorTopicYN="N" Type="Geographic">Mexico</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="N">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000635" MajorTopicYN="N">transmission</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="Y">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073887" MajorTopicYN="Y">Vaccination Coverage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017201" MajorTopicYN="N">Virus Shedding</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>10</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30376097</ArticleId><ArticleId IdType="pmc">PMC6206120</ArticleId><ArticleId IdType="doi">10.1093/cid/ciy650</ArticleId><ArticleId IdType="pii">5146694</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Benyesh-Melnick M, Melnick J, Rawls W et al. . Studies of the immunogenicity, communicability and genetic stability of oral poliovaccine administered during the winter. Am J Epidemiol 1967; 86:112&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">4378110</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander J, Howard E, Pallansch M. Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature. J Infect Dis 1997; 175:182.</Citation><ArticleIdList><ArticleId IdType="pubmed">9203713</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunn G, Klapsa D, Wilton T et al. . Twenty-eight years of poliovirus replication in an immunodeficient individual: impact on the global polio eradication initiative. PLoS Pathog 2015; 11: e1005114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4552295</ArticleId><ArticleId IdType="pubmed">26313548</ArticleId></ArticleIdList></Reference><Reference><Citation>Fine PE, Carneiro IA. Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis eradication initiative. Am J Epidemiol 1999; 150:1001&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10568615</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul JR, Horstmann DM, Riordan JT, et al. . An oral poliovirus vaccine trial in Costa Rica. Bull World Health Organ 1962; 26:311&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2555663</ArticleId><ArticleId IdType="pubmed">20604109</ArticleId></ArticleIdList></Reference><Reference><Citation>Troy SB, Ferreyra-Reyes L, Huang C, et al. . Community circulation patterns of oral polio vaccine serotypes 1, 2, and 3 after Mexican national immunization weeks. J Infect Dis 2014; 209:1693&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4017366</ArticleId><ArticleId IdType="pubmed">24367038</ArticleId></ArticleIdList></Reference><Reference><Citation>Mach O, Harish V, Khandait D, et al. . Prevalence of asymptomatic poliovirus infection in older children and adults in Northern India: analysis of contact and enhanced community surveillance, 2009. J Infect Dis 2014; 210:S252&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4663665</ArticleId><ArticleId IdType="pubmed">25316843</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandyopadhyay A, Garon J, Seib K, Orenstein W. Polio vaccination: past, present and future. Future Microbiol 2015; 791&#x2013;08, .</Citation><ArticleIdList><ArticleId IdType="pubmed">25824845</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organization. Polio Global Eradication Initiative annual report. World Health Organization, 2015 Available at: http://polioeradication.org/tools-and-library/policy-reports/annual-reports/. Accessed 11 April 2017.</Citation></Reference><Reference><Citation>
World Health Organization. Polio Global Eradication Initiative, 2017 Available at: http://polioeradication.org/polio-today/polio-now/. Accessed 31 December 2017.</Citation></Reference><Reference><Citation>Troy SB, Ferreyra-Reyes L, Canizales-Quintero S, et al.Real-time polymerase chain reaction analysis of sewage samples to determine oral polio vaccine circulation duration and mutation after Mexican national immunization weeks. J Pediatric Infect Dis Soc 2012; 1:223&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3529100</ArticleId><ArticleId IdType="pubmed">23667738</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organization. Polio Eradication &amp; Endgame Strategic Plan 2013&#x2013;2018. 2013 Available at: http://polioeradication.org/wp-content/uploads/2016/07/PEESP_EN_US.pdf. Accessed 11 April 2017.</Citation></Reference><Reference><Citation>
World Health Organization. Polio and the introduction of IPV. 2014 Available at: http://www.who.int/immunization/diseases/poliomyelitis/inactivated_polio_vaccine/Key_mess_FAQs.pdf. Accessed 11 April 2017.</Citation></Reference><Reference><Citation>Sarnquist C, Holubar M, Garc&#xed;a-Garc&#xed;a L, et al. Protocol paper: oral poliovirus vaccine transmissibility in communities after cessation of routine oral poliovirus vaccine immunization. Clin Infect Dis 2018; 67(S1):S114&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6206104</ArticleId><ArticleId IdType="pubmed">30376084</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilpatrick DR, Yang CF, Ching K, et al. . Rapid group-, serotype-, and vaccine strain-specific identification of poliovirus isolates by real-time reverse transcription-PCR using degenerate primers and probes containing deoxyinosine residues. J Clin Microbiol 2009; 47:1939&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2691077</ArticleId><ArticleId IdType="pubmed">19386844</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei L, Lin D, Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Stat Assoc 1989; 84:1065&#x2013;73.</Citation></Reference><Reference><Citation>Orelien J. Model Fitting in PROC GENMOD. SAS Users Group Internation. Statistics, Data Analysis, and Data Mining 264&#x2013;26. 2001. Available at: http://www2.sas.com/proceedings/sugi26/p264-26.pdf.</Citation></Reference><Reference><Citation>
The DHS Program. The DHS program&#x2014;Mexico: standard DHS, 1987, Available at: dhsprogram.com/what-we-do/survey/survey-display-11.cfm. Accessed 2 August 2017.</Citation></Reference><Reference><Citation>
CONEVAL
&#xcd;ndice de rezago social 2010 a nivel municipal y por localidad. | Available at: www.coneval.org.mx/Medicion/IRS/Paginas/%C3%8Dndice-de-Rezago-social-2010.aspx. Accessed 2 August 2017.</Citation></Reference><Reference><Citation>Holubar M, Troy SB, Nathoo K, et al. . Shedding of oral poliovirus vaccine (OPV) by HIV-infected and -uninfected mothers of OPV-vaccinated Zimbabwean infants. J Pediatric Infect Dis Soc 2017; 6:105&#x2013;08.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5907849</ArticleId><ArticleId IdType="pubmed">26759497</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelfand HM, Leblanc DR, Potash L, Clemmer DI, Fox JP. The spread of living attenuated strains of polioviruses in two communities in southern Louisiana. Am J Public Health Nations Health 1960; 50:767&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1373340</ArticleId><ArticleId IdType="pubmed">13827180</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelfand HM, Potash L, Leblanc DR, Fox JP. Intrafamilial and interfamilial spread of living vaccine strains of polioviruses. J Am Med Assoc 1959; 170:2039&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">13672796</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelfand HM, Leblanc DR, Fox JP, Conwell DP. Studies on the development of natural immunity to poliomyelitis in Louisiana. II. Description and analysis of episodes of infection observed in study group households. Am J Hyg 1957; 65:367&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">13424522</ArticleId></ArticleIdList></Reference><Reference><Citation>
Centers for Disease Control and Prevention
Travelers&#x2019; health. Available at: wwwnc.cdc.gov/travel/diseases/poliomyelitits. Accessed 20 May 2016.</Citation></Reference><Reference><Citation>Koprowski H, Norton TW, Jervis GA, et al. . Clinical investigations on attenuated strains of poliomyelitis virus: use as a method of immunization of children with living virus. J Am Med Assoc 1956; 160:954&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">13295050</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampton LM, Farrell M, Ramirez-Gonzalez A, et al. Immunization Systems Management Group of the Global Polio Eradication Initiative.Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine. MMWR Morb Mortal Wkly, 201665:934&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">27606675</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniuchi M, Famulare M, Zaman K, et al. Community transmission of type 2 poliovirus after cessation of trivalent oral polio vaccine in Bangladesh: an open-label cluster-randomised trial and modelling study. Lancet Infect Dis 2017; 17:1069&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5610141</ArticleId><ArticleId IdType="pubmed">28693854</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker E, Molodecky N, Pons-Salort M, O&#x2019;Reilly K, Grassly N. Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame. Expert Rev Vaccines 2015; 14:1113&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4673562</ArticleId><ArticleId IdType="pubmed">26159938</ArticleId></ArticleIdList></Reference><Reference><Citation>Hird TR, Grassly NC. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog 2012; 8:e1002599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3330118</ArticleId><ArticleId IdType="pubmed">22532797</ArticleId></ArticleIdList></Reference><Reference><Citation>Troy SB, Musingwini G, Halpern MS, et al. Vaccine poliovirus shedding and immune response to oral polio vaccine in HIV-infected and -uninfected Zimbabwean infants. J Infect Dis 2013; 208:672&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719901</ArticleId><ArticleId IdType="pubmed">23661792</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>